Pediatric Dermatology Vol. 22 No. 6 593–598, 2005

Subject Index, Volume 22, 2005

A
Acne
  infantile, oral isotretinoin for, 166–169, 357–359
  management in adolescent twins with Apert syndrome, 561–565
Acrocephalosyndactyly (Apert syndrome), acne management in, 561–565
Acrodermatitis enteropathica-like syndromes, without hypozincemia, 280–281(c)
Acute lymphoblastic leukemia (ALL)
  atypical pyoderma gangrenosum in, 543–545
  refractory *Demodex* folliculitis in, 407–411
Adnexal tumors with epidermal nevus syndrome, Spitz nevus and hypophosphatemic D-resistant rickets, 48–54
Africa, prevalence of pediatric skin disorders in, 6–9
Airway involvement, in infantile hemangioma, 389
Alagille syndrome, cutaneous manifestations, 11–14
ALCL (anaplastic large cell lymphoma), 22
Aleukemic leukemia cutis, congenital, spontaneous regression of, 26–29
ALL. *See* Acute lymphoblastic leukemia
Allergic contact dermatitis, to wooden toilet seat, 344–345
Alopecia areata, in infants, 82–83(c)
Aminoaciduria, with peeling skin syndrome, 314–316
Amniotic band syndrome, raised limb bands of infancy and, 346–349
Amyloidosis, familial cutaneous, 122–126
Anaplastic large cell lymphoma (ALCL), 22
Aneuploidy, 270–275
Antibiotic therapy, ecthyma gangrenosum-like lesions after, 453–456
Anti-CD20 monoclonal antibody therapy, for refractory pemphigus vulgaris, 461–463
Anticonvulsant-induced hypersensitivity syndrome, in premature infant, 71–74
Apert syndrome, acne management in, 561–565
Aplaisa cutis of scalp, familial nonmembranous, 213–216
Aplasia cutis
  familial nonmembranous of scalp, 213–216
  nevus psiloliparus and, 206–209
ARC syndrome, ichthyosis associated with, 539–541
Artificial light exposure
  melanoma and, 505–506
  nonmelanoma skin cancer and, 509
Atopic dermatitis
  after heart transplant in infants, 102–108
  contact sensitization after patch testing, 1–5
  gender-specific differences in eyelash length and, 576(c)
  impact on patient, family and society, 192–198
  on nipples and areolas, 64–66
  patch testing for egg allergy in, 109–111
  pimecrolimus cream for, 465–470
Atrial septal defect, with microscephaly-lymphoedema-chorioretinal-dysplasia syndrome, 373–374(c)
Autoimmune thyroiditis, acquired ichthyosis and hypertrichosis of, 447–449
Autosomal dominant disorder, precalcaneal congenital fibrolipomatous hamartoma, 353–356

B
Bacillus-Calmette-Guerin vaccination, scrofuloderma associated with, 179–180(c)
Bacterial infection treatment, ecthyma gangrenosum-like lesions after, 453–456
Balanitis xerotica obliterans, with phimosis, 305–308
Basal cell carcinoma, in phacomatosis pigmentokeratotica on sebaceous nevus, 46
B-cell lymphopenia, in *Mycoplasma pneumoniae* infection, 558–560
Becker nevus, with lichen planus, 328–329
Bed bug, skin disease associated with, 183–185
Bloom syndrome, in Indian child, 147–150, 285(c)
Book reviews
  Melanomas in Prepubescents (Mones & Ackerman), 578
  Warts, Diagnosis and Management: An Evidence-Basad Approach (Brodell & Johnson), 371
Buschke-Ollendorff syndrome, case reports of, 133–136

C
Café au lait macule, associated with heterochromia iridis, 177–178(c)
Calcinosis cutis, posttraumatic, 227–229
Calcipotriol, for giant viral wart, 375–376(c)
CD4+ CD56+ hematolymphoid malignancy, non-T, non-B, nonmyeloid, 19–22
CD68+ foam cells, in diffuse normolipemic plane xanthoma, 127–129
Celiac disease, skin disorders and, 376–377(c)
CGH (comparative genomic hybridization), 273
Choanal atresia, with dyskeratosis congenita, 31–34
Cholestasis, in Alagille syndrome, 11–14
Cimex lectularius, skin disease associated with, 183–185
CINCA (chronic infantile neurological, cutaneous and articular syndrome), with early articular manifestations, 222–225
Clarithromycin, for *Mycobacterium scrofulaceum* localized cutaneous infection, 476–478
Clear-cell hidradenoma, of forearm, 450–452
Clear cell papulosis, case report of, 268–269

Collagenase, for debridement, 472–474
Collagenoma, eruptive with papular elastorrhexis and nevus anelasticus, 153–156
Colon involvement, in atypical IgA/IgG pemphigus, 321–326
Comparative genomic hybridization (CGH), 273
Congenital anomalies
with infantile hemangioma, 389–390
malalignment of great toenails in dizygotic twins, 434–435
multiple, with infantile myofibromatosis, 281–282(c)
from p63 gene single point mutation, 415–419
of scalp, hair collar sign and vascular stains associated with, 200–204
Congenital disorders. *See specific congenital disorders*
Contact sensitization, after patch testing, long-term follow-up, 1–5
Corticosteroids, systemic, for Sweet syndrome, 525–528
Cutis verticis gyrata, in Noonan syndrome, 142–146
Cystine excretion, with peeling skin syndrome, 314–316

D
Deafness, congenital, with pigmented mosaicism and pseudoacne, 575(c)
Debridement, with collagenase, 472–474
Demodex folliculitis, refractory, in acute lymphoblastic leukemia, 407–411
Dermatitis, toilet seat contact, 344–345
Dermatophytoses, prevalence in Nigerian school children, 6–9
Dermatosis
acute febrile neutrophilic, case reports of, 525–528
congenital erosive and vesicular healing with reticulated supple scarring, 55–58
Dermoscopy
of congenital melanocytic nevus, 188–190
for evaluating depth of venular malformations, 283(c)
Dimples, bi-acromial, 412–414
Disomy, uniparental, 482–486
Drug-induced hypersensitivity syndrome, in premature infant, 71–74
Dubowitz syndrome, clinical report, 480–481
Dyskeratosis congenita, with associated choanal atresia, 31–34

E
Ecthyma gangrenosum-like lesions, after antibiotic therapy, 453–456
Eczema, atopic. *See* Atopic dermatitis
Egg allergy in atopic dermatitis, patch testing for, 109–111
Embryonal rhabdomyosarcoma, of tongue, 218–220
EMLA cream, purpura from, 566–568
Epidermal nevus syndrome with adnexal tumors, Spitz nevus and hypophosphatemic D-resistant rickets, 48–54
Epidermolysis bullosa, recessive dystrophic, large atypical melanocytic nevi in, 338–342
Erythema multiforme. *See* Stevens-Johnson syndrome
Erythema multiforme, with *Mycoplasma pneumoniae* infection, 558–560
Exanthem, petechial in *Parvovirus* B19 infection, 430–432
308-nm Excimer laser, safety/efficacy for localized psoriasis, 161–164
Eyelash length, gender-specific differences in atopic eczema patients, 576(c)

F
Fabry disease, atypical presentation of, 334–336
Face, infantile hemangiomas of, 390–391
FALDH (fatty aldehyde dehyrogenase), in fibroblast culture, in Sjögren-Larsson syndrome, 574(c)
Familial telangiectasia macularis eruptiva perstans, 488–489(c)
Family, impact of atopic dermatitis on, 192–198
Fas-mediated keratinocyte death, overlap of SJS-TEN and, 319
Fatty aldehyde dehyrogenase (FALDH), in fibroblast culture, in Sjögren-Larsson syndrome, 574(c)
FISH, multicolor, 273
Fluorescent in situ hybridization, 272
Focal dermal hypoplasia, with exuberant fat herniations and skeletal deformities, 420–422
Fox Fordyce disease, in prepubertal girl, 89–90(c)

G
Genetic factors
in infantile hemangiomas, 391
mutation, in ARC syndrome, 541
Geographic tongue, with nonpustular psoriasis, 83–8–85(c)
Glossitis, benign migratory with nonpustular psoriasis, 83–85(c)
Glycosylation disorders, congenital, 457–460
Goltz syndrome, with exuberant fat herniations and skeletal deformities, 420–422
Granuloma annulare, congenital subcutaneous, 234–236

H
Hair collar sign, congenital anomalies of scalp and, 200–204
Halo nevus, in congenital divided nevus of eyelid, 427–429
Hamartomas
autosomal dominant precalcaneal congenital fibrolipomatous, 355–356
eccrine angiomatous, differential diagnosis of, 175–176
Hanging fat sign, in congenital disorders of glycosylation, 457–460
Head lice infestation, prevalence in Izmir, Turkey, 372–373(c)
Heart transplantation in infancy, atopic eczema after, 102–108
Hemangiomas
hemifacial infantile with intracranial extension, 309–313
infantile, current knowledge and future directions, 383–404
proliferating of infancy, imiquimod cream for, 254–256
Hematolymphoid malignancy, non-T, non-B, nonmyeloid CD4+ CD56+, 19–22
Henoch-Schönlein purpura, with hyperimmunoglobulinemia D and periodic fever syndrome, 138–140
Herpetic whitlow, pediatric HIV-1 infection and, 119–120
Heterochromia iridis
café au lait macule associated with, 177–178(c)
hyperpigmented patch with, 572(c)
Histidine excretion, with peeling skin syndrome, 314–316
Histiocytosis
benign cephalic in British-American child, 444–446

congenital non-Langerhans cell, 40–43
HIV-1 infection, herpetic whitlow AND, 119–120
Hyperimmunoglobulinemia D, with periodic fever syndrome and Henoch-Schönlein purpura, 138–140
Hyperkeratosis
follicular with nutritional deficiency, 60–63
of papules and plaques, in phrynoderma, 60–63
with scleredema adultorum, 36–38
Hyperpigmented patch, with heterochromia iridis, 572(c)
Hypersensitivity syndrome, drug-induced in premature infant, 71–74
Hypertrichosis, acquired
in autoimmune thyroiditis, 447–449
during topical tacrolimus therapy for vitiligo, 86–87(c)
Hypophosphatemic D-resistant rickets, with epidermal nevus syndrome, adnexal tumors and Spitz nevus, 48–54

I
Ichthyosis
acquired, in autoimmune thyroiditis, 447–449
with ARC syndrome, 539–541
IgA pemphigus
clinical features, 324–326
variant, atypical IgA/IgG pemphigus, 321–326
Imiquimod, topical
for multiple trichoepitheliomas, 67–70
for proliferating hemangioma of infancy, 254–256
Immunodeficiency, with Sweet syndrome, IVIG for, 530–534
Impetigo, simulated by *Microsporum gypseum* tinea faciei, 536–538
Infliximab, for pyoderma gangrenosum in PAPA syndrome, 262–265
Intravenous immunoglobulin (IVIG)
for immunodeficiency with Sweet syndrome, 530–534
for Stevens-Johnson syndrome epidermal necrosis overlap, 317–320
Isotretinoin
for acne infantum, 166–169, 357–359
for acne management of twins with Apert syndrome, 561–565
for Papillon-Lefèvre syndrome, 378–379(c)
Itch intensity, children's ratings of, 97–101
IVIG. *See* Intravenous immunoglobulin

J
Japanese family, Buschke-Ollendorff syndrome in, 133–136
Juvenile xanthogranulomas
congenital non-Langerhans cell histiocytosis and, 40–43
with contralateral lymphadenopathy, 424–426

K
Karyotyping, traditional, 272
Keratosis follicularis spinulosa declavans, differential diagnosis, 170–174
Kidney dysfunction, in ARC syndrome, 541

L
Leg, unilateral congenital linear atrophoderma of Moulin, 350–354
Leprosy, epidemiologic study from Delhi, 489–490(c)
Leukocyte α-Gal-A deficiency, atypical Fabry disease and, 334–336
Lichen nitidus, generalized, 158–160
Lichen planus
with congenital Becker nevus, 328–329
demographic/clinical data on, 295–298
oral, 299–303
Lichen sclerosus et atrophicus, balanitis xerotica obliterans with phimosis, 305–308
Linear atrophoderma of Moulin, unilateral congenital of leg, 350–354
Linear scleroderma, with progressive hemifacial atrophy, 436–429
Lipoid proteinosis (Urbach-Weithe syndrome), differential diagnosis of, 266–267
Liver involvement
in infantile hemangiomas, 388–389
in xanthoma disseminatum, 550–552
Lobster claw deformity, with focal dermal hypoplasia, 420–422
Lofgren syndrome, case report, 366–367
Loose anagen hair syndrome, with uncombable, spun-glass hair, 230–233
Lupus erythematosus, congenital, 240–242
Lymphadenopathy, contralateral, with juvenile xanthogranuloma, 424–426
Lymphomas
differential diagnosis of, 21–22
extranodal T/NK cell, 22
hypopigmented mycosis fungoides, UVA1-light therapy for, 82(c)
precursor B cell lymphoblastic, 23–25

M
Malnutrition
with multifocal scrofuloderma and disseminated tuberculosis, 440–443
phrynoderma and, 60–63
Mastocytosis
bullous, case report of, 79–81
cutaneous, in India, 87–89(c)
unusual presentation of, 554–557
Measles, "wild-type," vaccine-associated, 130–132
Melanocytic proliferation, with vulvar lichen sclerosus, 276–278(c), 278–279(c)
Melanoma
artificial light exposure and, 505–506
components of UV radiation and, 502–504
incidence/mortality patterns, 502
phacomatosis pigmentokeratotica and, 46
in situ, in diffuse nail melanosis, 210–212
sun exposure and, 504–505
Melanonychia, longitudinal , subungual melanoma in situ and, 210–212

Methotrexate, for generalized pustular psoriasis, 85–86(c)
Michelin tire syndrome, in siblings, 245–249
Microscephaly-lymphoedema-chorioretinal-dysplasia syndrome, with atrial septal defect, 373–374(c)
Microsporum gypseum, tinea faciei, simulating dry impetigo, 536–538
MIRIAM study, gender-specific differences in eyelash length of, atopic eczema patients, 576(c)
Molluscum contagiosum, epidemiology of, 287–293
Mosaicism, pigmented, with congenital deafness and pseudoacne, 575(c)
Multicolor FISH, 273
Multiorgan disease, with *Mycoplasma pneumoniae* infection, 558–560
Mycobacterium scrofulaceum localized cutaneous infection, clarithromycin for, 476–478
Mycoplasma pneumoniae infection, persistent B-cell lymphopenia, multiorgan disease and erythema multiforme in, 558–560
Mycosis fungoides
hypopigmented, UVA1-light therapy for, 82(c)
with precursor B cell lymphoblastic lymphoma, 23–25
Myofibromatosis, infantile, with multiple congenital anomalies, 281–282(c)

N
Nails
congenital malalignment of tonails in dizygotic twins, 434–435
melanosis, melanoma in situ and, 210–212
in pachyonchia congenita tarda, 283–285(c)
Nevus. *See also* Spitz nevi
anelasticus, with papular elastorrhexis and eruptive collagenoma, 153–156
congenital melanocytic, dermoscopy of, 188–190
eyelid, with periocular vitiligo, 427–429
large atypical melanocytic, in recessive dystrophic epidermolysis bullosa, 338–342
psiloliparus with aplasia cutis, 206–209
sebaceous, basal cell carcinoma development in phacomatosis pigmentokeratotica and, 46
telangiectatic nevus with nevus anemicus, 276(c)
Nipples, atopic dermatitis on, 64–66
Nonmelanoma skin cancer
artificial light exposure and, 509
incidence/mortality patterns, 506
sun exposure and, 508
ultraviolet radiation and, 506–508
Noonan syndrome, cutis verticis gyrata in, 142–146
Nutritional deficiencies, phrynoderma and, 60–63

O
Ocular complications, of infantile hemangiomas, 387–388
Oligonucleotide primed in situ labeling (PRINS), 272–273
Oral mucosa involvement, in atypical IgA/IgG pemphigus, 321–326
Orbital complications, of infantile hemangiomas, 387–388

P
Pachyonchia congenita tarda, with nail manifestations, 283–285(c)
PAPA syndrome, pyoderma gangrenosum in, infliximab for, 262–265
Papules
acantholytic dyskeratosis of vulva, 237–239
clear cell papulosis, 268–269
confluent and reticulated papillomatosis with tinea versicolor, 331–333
elastorrhexis and nevus anelasticus in eruptive collagenoma, 153–156
hyperkeratotic, in phrynoderma, 60–63
Parvovirus B19 infection, with petechial exanthem in "bathing trunk" distribution, 430–432
Patch testing
contact sensitization, long-term follow-up, 1–5
for diagnosis of egg allergy in atopic dermatitis, 109–111
Paucity of bile interlobular ducts, cutaneous manifestations, 11–14
Peeling skin syndrome, with aminoaciduria, 314–316
Pemphigus, atypical IgA/IgG, 321–326
Pemphigus vulgaris, refractory, anti-CD20 monoclonal antibody therapy for, 461–463
Perianal pyramidal protrusion, infantile, 151–152
Periodic fever syndrome, with hyperimmunoglobulinemia D and Henoch-Schönlein purpura, 138–140
p63 gene mutations, single point, phenotypic manifestations from, 415–419
PHACES syndrome, absence, in hemifacial infantile hemangioma, 309–313
Phacomatosis pigmentokeratotica, long-term follow-up, 44–47
Phenytoin, drug-induced hypersensitivity syndrome in premature infant, 71–74
Phimosis, with balanitis xerotica obliterans, 305–308
Phrynoderma, 60–63
Pilomatricomas, multiple, associated with spina bifida, 178–179(c)
Pimecrolimus cream, for infants with atopic dermatitis, 465–470
Pityriasis lichenoides et varioliformis acuta (PLEVA), septic CD-30 positive febrile ulceronecrotic, 360–364
Pityriasis versicolor, prevalence in Nigerian school children, 6–9
Plaques, hyperkeratotic in phrynoderma, 60–63
PLEVA (Pityriasis lichenoides et varioliformis acuta), septic CD-30 positive febrile ulceronecrotic, 360–364
Poroma, eccrine, 279–280(c)
Posttraumatic calcinosis cutis, 227–228
Precursor B cell lymphoblastic lymphoma, with mycosis fungoides, 23–25
Prednisone, for Sweet syndrome, 525–528
Premature infant, drug-induced hypersensitivity syndrome in, 71–74
PRINS (oligonucleotide primed in situ labeling), 272–273
Progressive hemifacial atrophy, with linear scleroderma, 436–429

Pseudoacne, with congenital deafness and pigmented mosaicism, 575(c)
Psoriasis
308-nm excimer laser for, 161–164
generalized pustular, methotrexate for, 85–86(c)
nonpustular, with geographic tongue, 83–85(c)
primary annular plaque-type, 15–18
Purpura, after EMLA cream application, 566–568
Pustules
diffuse with changing clinical features, 250–252
in generalized psoriasis, methotrexate for, 85–86(c)
Pyoderma gangrenosum
atypical, in childhood ALL, 543–545
with PAPA syndrome, infliximab for, 262–265

Q
Quantitative fluorescence polymerase chain reaction, 274

R
Raised limb bands, amniotic band syndrome and, 346–349
Recessive dystrophic epidermolysis bullosa, large atypical melanocytic nevi in, 338–342
Rickets, with epidermal nevus syndrome, adnexal tumors and Spitz nevus, 48–54
Rituximab, for refractory pemphigus vulgaris, 461–463

S
Scabies, prevalence in Nigerian school children, 6–9
Scalp
congenital anomalies with hair collar sign and vascular stains, 200–204
familial nonmembranous aplasia cutis of, 213–216
School-based sun protection policies, for skin cancer prevention, 112–117, 513–519
Scleredema adultorum, with hyperkeratosis, 36–38
Scrofuloderma
following BCG vaccination, 179–180(c)
multifocal with disseminated tuberculosis in malnourished child, 440–443
Seborrheic dermatitis-like tinea faciei, 243–244
Sjögren-Larsson syndrome
case report, 569–570
similarities in Indian and central European patients, 574(C)
Skin cancer
prevention, school-based sun protection policies, for, 112–117, 513–519
tanning and, 501–509
Skin disorders
in atypical IgA/IgG pemphigus, 321–326
celiac disease and, 376–377(c)
prevalence, in Nigerian school children, 6–9
prevalence among children/adolescents in Turkey, 490–492(c)
SNARE protein pathway, in ARC syndrome, 541
Societal impact, of atopic dermatitis on, 192–198
Society for Pediatric Dermatology proceedings
June 2004 meeting, 91–95
July 2005 meeting, 579–587
SORTEN, mortality rate prediction in SJS-TEN, 319–320
Speckled lentiginous nevus (nevus spillus), phacomatosis pigmentokeratotica and, 46
Spina bifida, multiple pilomatricomas associated with, 178–179(c)
Spitz nevi
agminated, 546–548
with epidermal nevus syndrome, adnexal tumors and hypophosphatemic D-resistant rickets, 48–54
Staphylococcal scalded skin syndrome, differential diagnosis, 319
Stevens-Johnson syndrome
with *Mycoplasma pneumoniae* infection, 558–560
with toxic epidermal necrosis, IVIG for, 317–320
Sun exposure
of children in Northeast Italy, 520–523
melanoma and, 504–505
nonmelanoma skin cancer and, 508
school-based sun protection policies for skin cancer prevention, 112–117, 513–519
Sweet syndrome
case reports, 525–528
with immunodeficiency, IVIG for, 530–534
Syringoma, generalized eruptive, 492–493(c)

T
Tacrolimus, topical, for vitiligo, focal hypertrichosis after, 86–87(c)
Tanning
melanoma and, 505–506
nonmelanoma skin cancer and, 509
Thyroiditis, autoimmune, acquired ichthyosis and hypertrichosis of, 447–449
Thyroxine replacement therapy, for acquired ichthyosis and hypertrichosis of autoimmune thyroiditis, 447–449
Tinea capitis, first-line treatment, 372(c)
Tinea faciei
caused by *Microsporum gypseum* simulating dry impetigo, 536–538
seborrheic dermatitis-like, 243–244
Tinea versicolor, with confluent and reticulated papillomatosis in siblings, 331–333
Toenails, congenital malalignment in dizygotic twins, 434–435
Tongue, embryonal rhabdomyosarcoma of, 218–220
Touton giant cells, in diffuse normolipemic plane xanthoma, 127–129
Toxic epidermal necrosis with Stevens-Johnson syndrome, intravenous immunoglobulin for, 317–320
Tretinoin, topical, for multiple trichoepitheliomas, 67–70
Trichoepitheliomas, multiple, treatment of, 67–70
Trichorhinophalangeal syndrome, type I, differential diagnosis, 573(c)
Tuberculosis, disseminated with multifocal scrofuloderma in malnourished child, 440–443
Twin nevus, 276(c)
Twins
with Apert syndrome, acne management in, 561–565

dizygotic, congenital malalignment of great toenails in, 434–435
Twin spot genetic mechanism, 46

U
Ulceration, infantile hemangiomas and, 386–387
Ultraviolet radiation
nonmelanoma skin cancer and, 506–508
skin cancer and, 501–509
UVA1-light therapy, for hypopigmented mycosis fungoides, 82(c)
UV-B narrowband therapy, for vitiligo, 257–260
Uncombable hair syndrome, light microscopy diagnosis, 369–370
Urbach-Weithe syndrome, differential diagnosis of, 266–267

V
Vaccine-associated "wild-type" measles, 130–132
Vascular stains, congenital anomalies of scalp and, 200–204
Venular malformations, depth of, dermoscopic evaluation of, 283(c)
Vitamin A deficiency, phrynoderma and, 60–63
Vitamin B deficiency, in phrynoderma, 60–63
Vitamin E deficiency, in phrynoderma, 60–63
Vitiligo
periocular with onset around congenital divided nevus of eyelid, 427–429
UV-B narrowband therapy for, 257–260
Vulva
lichen sclerosus with melanocytic proliferation, 276–278(c), 278–279(c)
papular acantholytic dyskeratosis of, 237–239
unilateral swelling in mastocytosis, 554–557

W
Wart, giant viral, topical calcipotriol for, 375–376(c)
Wiedemann-Rautenstrauch syndrome (WRS)
case report, 75–78
differential diagnosis, 573(c)

X
Xanthomas
in Alagille syndrome, 11–14
diffuse normolipemic plane, 127–129
with hepatic involvement, 550–552
X-linked disorders
atypical recessive of lysosomal storage, 334–336
reticulate pigmentary, case reports of, 122–126

Z
Zinsser-Engman-Cole syndrome, with associated choanal atresia, 31–34

Pediatric Dermatology Vol. 22 No. 6 599–602, 2005

Author Index, Volume 22, 2005

A
Abdulla F.R., 501
Abenavoli L., 376(c)
Addolorato G., 376(c)
Agrawal S.K., 440
Akar A., 317
Akisu C., 372(c)
Aksoy U., 372(c)
Aktaş A., 179(c)
Albrecht-Nebe H., 127
Aliağaoğlu C., 179(c)
Allen D.M., 60
Almeida P., 75, 573(c)
Al-Mutairi N., 158, 366
Alomar A., 213
Alonso V., 575(c)
Alvarez E., 11
Amato L., 64
Anderson R.C., 122
Ang G., 350
Antaya R.J., 153
Antonovich D.D., 210
Anyane-Yeboa K., 142
Arca E., 317
Arcangeli F., 279(c)
Argenziano G., 188
Arn P., 415
Arun J., 158
Arya L.S., 543
Asial R., 206
Atasoy M., 179(c), 550
Athanikar S.B., 280(c)
Audring H., 127
Avendaño M., 237

B
Bakhshi S., 543
Balkrishan R., 192
Bañuls J., 480
Barbagallo T., 257, 447
Barilla D., 465
Barnes C.J., 166
Barranco C., 338
Baselga E., 213, 383
Batra V.V., 328
Bauer J., 102
Behrendt H., 576(c)
Beillard C., 412
Bellani E., 257, 447
Benjamin L.T., 561
Berggren K.L., 130
Bernardi S., 119
Bernard P., 222
Berti S., 64
Bertoli R., 420
Betlloch I., 480
Bischoff J., 383
Blume-Peytavi U., 127
Bohnsack J.F., 360
Bonte M.D.C., 206
Boon L., 383
Borroni G., 257, 447
Boukef S., 245
Boyer K.M., 130
Brandling-Bennett H.A., 569
Brathwaite N., 513
Braue A., 287
Braun-Falco M., 573(c)
Brazzelli V., 257, 447
Bruckner A.L., 321
Buchenau W., 355
Buquicchio R., 558
Burtin P., 465
Büyukavci M., 550

C
Cabrera H., 11
Cáceres M.R., 227
Calcaterra V., 447
Cambiaghi S., 83(c), 243
Candan I., 434
Carder K.R., 15, 122
Carney J.F., 254
Carroll C.L., 192
Casas J., 227
Cassano N., 558
Castelli-Gattinara G., 119
Castello M., 257
Cavalli R., 83(c)
Cerio R., 444
Chamlin S., 346
Chamlin S.L., 91, 369, 383, 457, 579
Chang C.L., 476
Chang M.W., 331
Chaouechi S., 245
Chaturvedi K.U., 283(c)
Chen M.-D., 280(c)
Chiarini C., 64
Choi H.-J., 539
Choi J.-H., 539
Chong W.-S., 268
Choudhury S., 334
Chou Y.-C., 23
Ciocca M., 11
Cirocco A., 218, 237
Coffin C.M., 200, 525
Cohen B., 230
Colmenero I., 206
Colonna C., 83(c)
Cork M.J., 373(c)
Costa A.R., 536
Craido P.R., 536
Cunha V.S., 372(c)
Cunningham B.B., 31, 166

D
Da Costa Pereira F., 48
Dadzie O., 44, 444
Dagregorio G., 412
Daikoku N., 453
Dallar Y., 472
Davis L.S., 151
DeAloe G., 234
De Ayala Casado E.L., 86(c)
De Davila M.T., 11
Delibas S.B., 372(c)
Delmaestro D., 420
De Lorenzi G., 376(c)
De Lucas Laguna R., 86(c)
Del Vecchio G.C., 558
De Mattia D., 558
Demirkesen C., 36
De Oliveiera Ramos R., 536
Dervis E., 436

Deshmukh N.S., 280(c)
Diehl E.S., 372(c)
Diociaiuti A., 119, 240
Dogra S., 85(c)
Domenici R., 250
Domínguez-Soto L., 295
Drolet B.A., 213, 276(c), 383
Dyer J.A., 346, 457

E
Eblin M.-E., 465
Ehsan A., 19
Eichenfield L.F., 166, 465
Eksioglu H.M., 472
El-Azhary R.A., 377(c)
El Hachem M., 119, 240
Engin B., 36
Engstrom C.W., 254
Erbil A.H., 317
Erdem T., 179(c)
Erdeve O., 472
Ersoy S., 309
Ertekin V., 550
Eschard C., 222
Esterly N.B., 60, 213, 383, 572(c)

F
Fabbri P., 64
Fass J., 19
Favot F., 520
Febrer Bosch I., 44
Feldman S.R., 192, 501
Ferguson A.D., 373(c)
Fimiani M., 234
Fitzpatrick J.E., 321
Fleet S.L., 151
Fleischer A.B. Jr., 192
Fortea Baixauli J.M., 44
Foti C., 558
Fox L.P., 142
Francis N., 40
Freitag F.M., 372(c)
Frieden I.J., 276(c), 383
Friedlander S.F., 383
Fuchs S.C., 372(c)
Fujiwara M., 450

G
Gallardo F., 338
Garcia M.A., 11
Garg V.K., 283(c), 328, 489(c)
Garman M.E., 170
Garzon M.C., 142, 383
Gasbarrini G., 376(c)
Gatter K., 26
Geller A.C., 112
Geyer A.S., 142
Giachetti A., 227
Gieler U., 102
Ginter-Hanselmayer G., 372(c)
Giraldi L., 119, 240
Giusti F., 1, 109
Glasgow M.A., 546
Goddard D.S., 383
González F., 218, 237
Gorani A., 243
Gottlieb A.B., 161, 465
Grant-Kels J.M., 210
Grimwood R.E., 19
Grin C., 210
Grover C., 283(c), 328, 489(c)
Guareschi E., 488(c), 566
Guerra-Tapia A., 427
Guerrini V., 488(c)
Guill C.L., 15
Guillet G., 412
Gupta A., 372(c)
Gupta S., 89(c)
Gür A.R., 317
Gurunluoglu R., 434

H
Haggstrom A.N., 383
Haliasos E., 530
Hall R.P. III, 461
Handa S., 85(c)
Hansen H., 415
Happle R., 206
Hashimoto T., 321
Hassanein A.H., 158, 366
Hassanein A.M., 278(c)
Hazen P.G., 254
Henderson W., 530
Heptulla R.A., 554
Hermosa J.M.H., 430
Hernández B., 75
Hernández J., 75
Herranz Pinto P., 86(c)
Herrick J.L., 19
Herron M.D., 200, 360, 407, 525
Hicks J., 55, 554
Hoang M.P., 15
Hofmann M., 127
Holme S.A., 266, 344
Hong H.-S., 23
Hopster D., 444
Huerta-Brogeras M., 430
Huss-Marp J., 576(c)
Hyde P.M., 350

I
Iauriola M.M., 447
Iázaro-Ochaita P., 430
Ihn H., 492(c)
Inamadar A.C., 147, 175, 280(c), 285(c), 314
Isarría M.J., 427
Ishihara T., 453
Ishikawa T., 453
Izquierdo J.A.A., 430

J
Jaafoura J., 245
Jang H.-S., 476
Jiménez C., 218
Jo J.-H., 476
Jorda E., 575(c)
Joshi A., 366

K
Kalis B., 222
Kamoun M.R., 245
Kanwar A.J., 82(c), 85(c), 87(c), 89(c)
Karabulut A.A., 472
Katz B.J., 161
Kaufmann R., 465
Kaur M., 501
Kawamura A., 133
Kelly H., 287
Khaitan B.K., 378(c)
Kharfi M., 245
Kim J., 122
Kim M.-B., 476
Kincannon J.M., 546
Kinney J.P., 112
Király L., 305
Kirke S., 424
Kirsner R.S., 513
Kishida E.S., 48
Kiss A., 305
Koh J.-K., 539
Kong H.H., 461
Korkmaz A., 71
Köse O., 317
Kotogyan A., 36
Krafchik B.R., 266
Krämer U., 102, 576(c)
Kraus E.W., 19

Kreitchmann R., 372(c)
Krowchuk D., 501
Kumaran M.S., 85(c)
Kumarasinghe S.P.W., 268
Kuo T.-T., 23
Kupfer J., 102
Kus S., 434
Kutasy B., 305
Kwok Y.-K., 79
Kwong P.C., 415
Kwon K.-S., 476
Kwon Y.-W., 476

L
Labandeira J., 375(c)
Laeijendecker R., 299
Lain E.L., 546
Landers M.C., 26
Langley R.G., 465
Lapunzina P., 11
Larizza D., 447
Larralde M., 227
Larregue M., 412
Lee A.J., 230
Lee J., 166
Lee J.-B., 476
Lee J.B., 350
Lee M.-W., 539
Lee Y.-S., 79
Leggio L., 376(c)
Lenane P., 266
Lener E.V., 31
Levy M., 55
Leys C., 222
Liange M.G., 569
Lloreta J., 338
Longo-Imedio M.I., 430
Lozano A.M., 161
Lucas E., 420
Luis-Montoya P., 295
Luti L., 250

M
Mahiques Santos L., 44
Maino K.L., 230
Malempati S., 26
Malhotra A.K., 378(c)
Malvehy J., 338
Mancini A.J., 309, 383
Mantovani L., 1
Manuel J.C., 192
Marinho T., 420
Maronn M., 60
Marti M., 75
Martinez-Menchón T., 44
Martini P., 250
Martín J.M., 575(c)
Martire B., 558
Mascaró-Galy J.M., 338
Mathes E.W., 383
Mat M.C., 36
Mayou S.C., 40
Mazzatenta C., 250
Medri M., 566
Meehan S., 334
Merksz M., 305
Metry D.W., 170, 178(c), 554
Metz B.J., 55
Meyer P., 355
Mills C.M., 344
Miranda S.B., 420
Miyagawa S., 453
Möhrenschlager M., 573(c), 576(c)
Moon K.-C., 539
Morelli J.G., 321
Morgan A.J., 554
Morrell D.S., 530
Motte J., 222
Muniz Silva M.A., 48
Muraoka M., 450
Murphy F., 161

N
Nakajima M., 453
Nanda S., 283(c), 328, 489(c)
Ndahi A., 6
Neri I., 279(c), 488(c), 566
Neumann H.A.M., 299
Niemeier V., 102
Nieto O., 206
Nişcanci M., 317
Nopper A.J., 383
North P.E., 383
Nose K., 450
Nour-Eldin O., 158, 366
Nunez-Gussman J., 170

O
Ochiai T., 133
Ogunbiyi A.O., 6
Oh C.-K., 476
Ong B.-H, 268
Oranje A.P., 299
O'Reilly M.A., 407
Oriani A., 243
O'Riordan D. L., 112
Orlandi C., 279(c)
Orlow S.J., 276(c)
Oscar R.F., 218
Oschmann P., 102
Owoaje E., 6
Ozawa T., 450
Özdemir S., 179(c)
Ozdogan H., 36
Ozkoc S., 372(c)

P
Pahlajani N., 161
Palit A., 147, 175, 280(c), 285(c), 314
Pallotta R., 572(c), 573(c)
Palma P., 119
Pandhi D., 440
Paone C., 240
Paradisi M., 240
Paredes C., 375(c)
Parente A., 376(c)
Pariser D., 465
Parker D.F., 513
Pascual J.C., 480
Pascual V., 262
Passoth P.R., 102
Pastor M.A., 357
Patrizi A., 279(c), 488(c), 566
Patrone P., 520
Pepe P., 1
Pérez-Oliva N., 283(c)
Peterson J., 19
Petrillo G., 188
Pianigiani E., 234
Pielop J.A., 178(c)
Prats Caelles I., 86(c)
Prestinari F., 257, 447
Prieur A.-M., 222
Prose N.S., 183, 461
Pujol R.M., 338
Punaro M., 262
Puri S., 328

Q
Quickenstein E., 520
Quinlan K., 177(c)

R
Ramonet M., 11
Reddy B.S.N., 283(c), 328, 489(c)
Reep M.D., 254
Ring J., 573(c), 576(c)
Risulo M., 234

Rittey C.D.C., 373(c)
Rocha de Souza S.F., 536
Rodríguez M., 227
Rosenberg S., 112
Ross G., 287
Roupe G., 82(c)
Roveda E., 257
Roy J., 554
Rubenstein D.S., 530
Ruocco E., 188
Ryder H.F., 153

S
Saeki H., 492(c)
Sáenz A.M., 218, 237
Sahin S., 372(c)
Sakurai Y., 453
Sampagavi V.V., 175, 280(c)
Sanches J.A. Jr., 48
Sandhu K., 82(c), 87(c), 89(c)
Saponari A., 572(c), 573(c)
Sardi J.R., 218, 237
Saulsbury F.T., 138
Savas N., 490(c)
Savoia F., 566
Sbano P., 234
Schachner L.A., 561
Schaffer J.V., 276(c)
Schmidli H., 465
Schroeder T.L., 26
Scott G., 465
Seidenari S., 1, 109
Sekerel B., 71
Selimoglu A., 550
Serarslan G., 490(c)
Sethuraman G., 378(c), 543
Shamban J., 112
Sharma V.K., 378(c)
Shehan J.M., 377(c)
Shih I.-H., 23
Shin H.T., 331, 334
Shwayder T., 177(c), 572(c)
Sidwell R.U., 40
Siegel D.B., 482
Siegel D.H., 270, 383
Silva C.S., 536
Silverman R.A., 371
Singal A., 440
Singh M.K., 543
Slater D.N., 40
Slavotinek A., 482
Slygh C., 112
Smolle J., 372(c)
Soder B., 530
Soennichsen K., 355
Song Y.-M., 280(c)
Sotto M.N., 48
Soyer H.P., 188
Sperling L., 230
Staab D., 465
Steele J.A., 415
Stein J.A., 331
Sterry W., 127
Stichweh D.S., 262
Stinco G., 520
Stone N.M., 344
Strauss R.M., 373(c)
Suárez-Peñaranda J.M., 375(c)
Suzuki H., 133
Sybert V.P., 270

T
Tahmaz E., 434
Tamaki K., 492(c)
Tanaka M., 453
Tank B., 299
Tan-Kinoshita M., 133
Tanphaichitr A., 254
Taylor A.E.M., 424
Tay Y.-K., 79
Tejada F., 513
Ter Poorten M.C., 183
Tharp M., 130
Thomas A., 513
Tichy E.H., 19
Tilford D., 26
Tiras U., 472
Toll A., 338
Tom W.L., 31
Toribio J., 375(c)
Torrelo A., 206, 213, 357
Trapido E.J., 513
Trefzer U., 127
Trowers A.B., 561
Tsunemi Y., 492(c)
Turgeon K.L., 254

U
Urquhart J.L., 67
Uygur T., 434

V
Vabres P., 412
Valent F., 520
Vanderhooft S.L., 200, 360, 407, 525
Van Joost T., 299
Varigos G., 287
Vasconcellos C., 536
Vásquez-Blanco M., 375(c)
Vázquez-Lopez F., 283(c)
Vega-Memije E., 295
Vergara G., 480
Vilata Corell J.J., 44
Villalón G., 575(c)

W
Wahlgren C.-F., 97
Wakeel R., 444
Ware R.E., 461
Weidinger S., 576(c)
Weinstein J.M., 369
Weston W.L., 67, 321
White C., 26
Wickiser J.E., 138
Wilkinson E.J., 278(c)
Williford P.M., 501
Windebank K., 424
Winik B., 206
Winters C.J., 457
Wood K., 424

Y
Yang C.-P., 23
Yelikar B.R., 175
Yigit S., 71
Yildirim U., 550
Yoshioka A., 453

Z
Zalaudek I., 188
Zambrano A., 206, 213, 357
Zanchi M., 520
Zanchini R., 188
Zappel K., 127
Zaraa I., 245
Zekri S., 245
Zinn A.R., 122